Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.80.

Several research firms have recently issued reports on INO. Piper Sandler began coverage on Inovio Pharmaceuticals in a report on Wednesday. They set an "overweight" rating and a $5.00 price objective on the stock. HC Wainwright reiterated a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, March 19th. Royal Bank Of Canada reissued a "sector perform" rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. Finally, Oppenheimer cut their price objective on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently bought and sold shares of INO. Nomura Holdings Inc. acquired a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $28,000. Alpine Global Management LLC acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $31,000. Freedom Investment Management Inc. acquired a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 5,894 shares during the period. Finally, Bank of Montreal Can acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $43,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO traded down $0.03 during trading hours on Wednesday, reaching $1.36. 1,782,842 shares of the company traded hands, compared to its average volume of 810,646. The firm's 50-day moving average is $1.93 and its 200-day moving average is $1.93. The stock has a market cap of $49.87 million, a P/E ratio of -0.43 and a beta of 1.31. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $12.33.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.23. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million. As a group, research analysts predict that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.